When rich companies with politically-connected lobbyists and seats on government-appointed bodies bend policies for their own ends, we are in serious trouble. In the US, many senior figures from the Genetically Modified Organisms industry have moved with ease to take up positions with the Food and Drug Administration. In 1998, senior Monsanto figure Phil Angell stated in the New York Times Magazine that Monsanto should not have to vouch for the safety of biotech food and that its interest is in selling as much of it as possible, while assuring its safety is the FDA’s job.